Dissertation Dr. med. Ekkehard Reischle - Privatklinik Dr. Reischle
Dissertation Dr. med. Ekkehard Reischle - Privatklinik Dr. Reischle
Dissertation Dr. med. Ekkehard Reischle - Privatklinik Dr. Reischle
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
ing.Psychopharmacology (Berl) 124(1-2):57-73(1996)<br />
128 Woods SW.Chlorpromazine equivalent doses for the newer atypical antipsychotics.J Clin Psychiatry<br />
64(6):663-7(2003)<br />
129 Davis JM, Chen N. Dose response and dose equivalence of antipsychotics.J Clin Psychopharma<br />
col.;24(2):192-208 (2004)<br />
130 Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone.<br />
J Clin Psychopharmacol.17(3):194-201 (1997)<br />
131 Seeman P, Tedesco JL, Lee T, Chau-Wong M, Muller P, Bowles J, Whitaker PM, McManus C, Tittler M,<br />
Weinreich P, Friend WC, Brown GM. Dopamine receptors in the central nervous system.<br />
Fed Proc 37(2):131-6.(1978)<br />
132 Bandelow, B.,Bleich, S.,Kropp, S. Handbuch Psychopharmaka.Hogrefe Verlag Göttingen Bern Toronto<br />
Seattle. 2., überarbeitete Auflage:116 (2004)<br />
133 Stille G. [Pharmacology of catatonigenic agents. 5. The effect of neuroleptics] Arzneimittelforschung<br />
21(6):800-8 (1971)<br />
134 Julou,L.et al. Comparaison des effects des neuroleptiques dans divers tests, en administration unique et en<br />
administrations repetees. Hypotheses sur la significationdes test utilises et leur valeur previsionnelle.in<br />
Neuro-Psycho-pharmacology, Ed.Brill, H.,Cole, J.O.,Deniker, P.,Hippius,H.,Bradley, P.B.,ICS 129, Ex<br />
cerpta Medica Foundation, Amsterdam : 293 (1967)<br />
135 Moore, N.A.et al..The pharmacology of olanzapine and other new antipsychotic agents.Curr.<br />
Opin.Invest.<strong>Dr</strong>ugs 2(4):281-293 (1993)<br />
136 Liebermann, J.A., Stroup,T.S., Mc Evoy, J.P. et al.or the CATIE Investigators .Effectiveness of antipsychotic<br />
drugs in patients with chronic schizophrenia.N Engl J Med 353 : 1209-1233 (2005)<br />
137 Jones P.B. et al.Randomized controlled trial of the effect on Quality of Life of second- versus first- generation<br />
antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic <strong>Dr</strong>ugs in schizo<br />
phrenia Study (CUtLASS1).Arch Gen Psychiatry 63:1079-1087 (2006)<br />
138 Steinert T. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics]. Psychiatr Prax.:<br />
34(5) Jul: 255-7. (2007)<br />
139 Mintz J, Kopelowicz A. CUtLASS confirms CATIE.Arch Gen Psychiatry.Aug;64(8):978(2007)<br />
140 Tandon R, Carpenter WT, Davis JM. First- and second-generation antipsychotics: learning from Cut<br />
LASS and CATIE.Arch Gen Psychiatry. 64(8) Aug:977-8 (2007)<br />
141 Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost UtilityOf The<br />
latest Antipsychotic <strong>Dr</strong>ugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of<br />
Intervention Effectiveness (CATIE).Arch Gen Psychiatry.Oct;63(10):1069-72. (2006)<br />
142 Möller HJ. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer<br />
from the CATIE study.Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):371-2.<br />
143 NICE (National Institute for Clinical Excellence).Technology Appraisal Guidance<br />
No.43.web:www.nice.org.uk (2006)<br />
85
Change language